secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCEPT INC (—)
CIK:        0001044378
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001193125-23-144030
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 3.01, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biocept Q1 revenue collapses to $0.7M; faces Nasdaq delisting for low equity
----------------------------------------------------------------------------

- Net revenue fell to $0.7M from $19.9M YoY; COVID-19 testing ceased in Feb 2023.
- Net loss attributable to common stockholders was $7.1M ($0.41/share) vs $2.2M ($0.13) a year ago.
- Cash dropped to $6.8M from $12.9M at year-end 2022; equity at $2.4M below Nasdaq minimum.
- Expects Nasdaq delisting notice; must submit compliance plan within 45 days.
- Stockholders approved reverse stock split between 1:15 and 1:30 ratios.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1044378/000119312523144030/0001193125-23-144030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1044378/000119312523144030/d420466d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-144030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer